<DOC>
	<DOCNO>NCT01585623</DOCNO>
	<brief_summary>Primary Objective : - To assess effect 15-day repeat oral dos 500 mg SAR302503 cytochrome P450 activity use CYP probe cocktail ( 2C19 , 2D6 3A4 ) . - To document pharmacokinetics SAR302503 repeat 500 mg oral daily dos . Secondary Objectives : - To assess safety profile 15-day repeated oral dos 500 mg SAR302503 Segment 1 - To characterize safety tolerability 28-day consecutive dos 500 mg SAR302503 Segment 2 - To determine antitumor activity Segment 2</brief_summary>
	<brief_title>Drug Interaction Study SAR302503 Patients With Solid Tumor</brief_title>
	<detailed_description>The duration study individual patient include period assess eligibility ( screen period 21 day ) , follow treatment period least 15 day study treatment , end-of-treatment visit least 30 day follow last administration study drug . However , treatment may continue patient receive benefit unacceptable toxicity meet study withdrawal criterion .</detailed_description>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm advanced solid malignancy metastatic unresectable , standard curative measure exist Signed inform consent Exclusion criterion : Less 18 year age . Limited physical functioning ( evaluated Eastern Cooperative Oncology Group ( ECOG ) scale ) Inability follow study requirement schedule Treatment cancer within 3 week study , concurrent treatment another clinical trial anticancer therapy Serious medical illness time study and/or significantly abnormal lab report Lack pregnancy contraception ( woman childbearing potential ) , pregnancy , breast feeding . Men partner woman childbearing potential , unless agree use effective contraception study drug Continued toxic effect prior chemotherapy Evidence concurrent active malignancy Other concurrent serious illness medical condition Cardiac abnormality include bradycardia , AV block conduction defect ECG , patient take beta blocker . Patients InsulinDependent Diabetes Mellitus . Patients know active ( acute chronic ) hepatitis A , B , C , hepatitis B C carry . Prior history chronic liver disease ( e.g. , chronic alcoholic liver disease , autoimmune hepatitis , sclerosing cholangitis , primary biliary cirrhosis , hemachromatosis , nonalcoholic steatohepatitis [ NASH ] ) . Inadequate organ function History partial total gastrectomy , , opinion investigator , disorder would inhibit absorption oral medication . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>